Core Viewpoint - Dahua Jixian has initiated coverage on Yimaitong (02192) with a "Buy" rating and a target price of HKD 13.5, corresponding to a projected P/E ratio of approximately 24.1 times for 2026 [1] Company Overview - Yimaitong is recognized as a leading physician platform in China, covering 88% of practicing physicians nationwide [1] - The company operates in a B2B niche market centered around physicians, which complements consumer-focused peers in the industry [1] Financial Projections - The company is expected to maintain a light asset and high-profit margin model, supporting an average annual compound growth rate of 17% in revenue and 15% in adjusted net profit from 2025 to 2027 [1] - Yimaitong's net cash position and high-profit margin outlook are viewed positively, with a potential dividend payout ratio estimated between 50% to 60% [1]

Core Viewpoint - Dahua Jixian has initiated coverage on Yimaitong (02192) with a "Buy" rating and a target price of HKD 13.5, corresponding to a projected P/E ratio of approximately 24.1 times for 2026 [1] Group 1: Company Overview - Yimaitong is recognized as a leading physician platform in China, covering 88% of practicing physicians nationwide [1] - The company operates in a B2B niche market centered around physicians, which complements consumer-focused peers in the industry [1] Group 2: Financial Projections - The company is expected to achieve a compound annual growth rate (CAGR) of 17% in revenue and 15% in adjusted net profit from 2025 to 2027 [1] - Yimaitong's business model is characterized by light asset utilization and high profit margins, supporting its financial growth outlook [1] Group 3: Cash and Dividend Outlook - The company is anticipated to maintain a strong net cash position and high profit margin prospects [1] - Potential dividend payout ratio is estimated to be between 50% and 60% [1]